Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)
This grant funds the development of noninvasive electronic nose technology to detect disease biomarkers from human skin for real-time diagnosis and monitoring, aiming to improve and complement traditional diagnostic methods.
Funder: National Institutes of Health (NIH)
Due Dates: June 5, 2026 (Estimated)
Funding Amounts: No specified ceiling or floor; funding amount to be determined (Cooperative Agreement mechanism)
Summary: Supports development of electronic nose technologies for noninvasive disease diagnosis and monitoring via detection of volatile organic compounds.
Key Information: This is a forecasted opportunity; dates and details may change.
Description
This opportunity seeks to advance electronic nose technologies that mimic human olfaction, aiming to create robust diagnostic platforms capable of real-time, noninvasive disease detection. Building on previous efforts that established the feasibility of biosensing volatile organic compound (VOC) signatures using systems engineering and artificial intelligence, this program targets the development of improved sensing, detection, and analytical platforms. These technologies are intended for integration into tools for diagnosing and monitoring disease in everyday, non-clinical settings, offering a complement to traditional, invasive diagnostic procedures. The initiative aligns with the National Center for Advancing Translational Sciences' (NCATS) vision to accelerate the availability of treatments for a broad range of conditions.
